Catherine Boileau
Responsable de l'équipe, Cardiovascular structural diseases
Institution:
USPC - SET - SVS
Summary
Published articles Show More
Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis
...Published in European Respiratory Journal
Pulmonary fibrosis is a fatal disease with progressive loss of respiratory function. Defective telomere maintenance leading to telomere shortening is a cause of pulmonary fibrosis, as mutations in the telomerase component genes TERT (reverse transcriptase) and TERC (RNA component) are found in 15% of familial pulmonary fibrosis (FPF) cases. However...
Marfan Sartan: a randomized, double-blind, placebo-controlled trial
...
AIMS: To evaluate the benefit of adding Losartan to baseline therapy in patients with Marfan syndrome (MFS). METHODS AND RESULTS: A double-blind, randomized, multi-centre, placebo-controlled, add on trial comparing Losartan (50 mg when \textless50 kg, 100 mg otherwise) vs. placebo in patients with MFS according to Ghent criteria, age \textgreater10...
Design and rationale of a prospective, collaborative meta-analysis of all randomized controlled trials of angiotensin re...
...
Published in Japanese Journal of Pediatric Pulmonology
A prospective, collaborative meta-analysis based on individual patient data from all randomized trials in Marfan syndrome of (i) ARBs versus placebo (or open-label control) and (ii) ARBs versus β-blockers will be performed. A prospective study design, in which the principal hypotheses, trial eligibility criteria, analyses, and methods are specified...
Experience
Responsable de l'équipe
Université Paris Diderot
Cardiovascular structural diseases; U1148, Laboratory for Vascular Translational Science; UFR de Médecine
